Recurrent Osteosarcoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02867592Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsTreatment